Influence of low molecular weight heparin on cancer patients’ survival

<p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. Th...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	V. V. Ptushkin [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2014

Schlagwörter:	ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival

Übergeordnetes Werk:	In: Онкогематология - ABV-press, 2015, 8(2014), 2, Seite 70-76
Übergeordnetes Werk:	volume:8 ; year:2014 ; number:2 ; pages:70-76

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ01920468X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ01920468X
003	DE-627
005	20230310204639.0
007	cr uuu---uuuuu
008	230226s2014 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ01920468X
035			\|a (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC633-647.5
100	0		\|a V. V. Ptushkin \|e verfasserin \|4 aut
245	1	0	\|a Influence of low molecular weight heparin on cancer patients’ survival
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p<
650		4	\|a ultra low molecular weight heparins
650		4	\|a low molecular weight heparins
650		4	\|a cancer
650		4	\|a metastasis
650		4	\|a survival
653		0	\|a Diseases of the blood and blood-forming organs
773	0	8	\|i In \|t Онкогематология \|d ABV-press, 2015 \|g 8(2014), 2, Seite 70-76 \|w (DE-627)1736704621 \|x 24134023 \|7 nnns
773	1	8	\|g volume:8 \|g year:2014 \|g number:2 \|g pages:70-76
856	4	0	\|u https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae \|z kostenfrei
856	4	0	\|u http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1818-8346 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 8 \|j 2014 \|e 2 \|h 70-76

Indexfelder

author_variant	v v p vvp
matchkey_str	article:24134023:2014----::nlecolwoeuawihhprnnacr
hierarchy_sort_str	2014
callnumber-subject-code	RC
publishDate	2014
allfields	(DE-627)DOAJ01920468X (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae DE-627 ger DE-627 rakwb rus RC633-647.5 V. V. Ptushkin verfasserin aut Influence of low molecular weight heparin on cancer patients’ survival 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p< ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival Diseases of the blood and blood-forming organs In Онкогематология ABV-press, 2015 8(2014), 2, Seite 70-76 (DE-627)1736704621 24134023 nnns volume:8 year:2014 number:2 pages:70-76 https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae kostenfrei http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 kostenfrei https://doaj.org/toc/1818-8346 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 2 70-76
spelling	(DE-627)DOAJ01920468X (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae DE-627 ger DE-627 rakwb rus RC633-647.5 V. V. Ptushkin verfasserin aut Influence of low molecular weight heparin on cancer patients’ survival 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p< ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival Diseases of the blood and blood-forming organs In Онкогематология ABV-press, 2015 8(2014), 2, Seite 70-76 (DE-627)1736704621 24134023 nnns volume:8 year:2014 number:2 pages:70-76 https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae kostenfrei http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 kostenfrei https://doaj.org/toc/1818-8346 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 2 70-76
allfields_unstemmed	(DE-627)DOAJ01920468X (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae DE-627 ger DE-627 rakwb rus RC633-647.5 V. V. Ptushkin verfasserin aut Influence of low molecular weight heparin on cancer patients’ survival 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p< ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival Diseases of the blood and blood-forming organs In Онкогематология ABV-press, 2015 8(2014), 2, Seite 70-76 (DE-627)1736704621 24134023 nnns volume:8 year:2014 number:2 pages:70-76 https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae kostenfrei http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 kostenfrei https://doaj.org/toc/1818-8346 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 2 70-76
allfieldsGer	(DE-627)DOAJ01920468X (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae DE-627 ger DE-627 rakwb rus RC633-647.5 V. V. Ptushkin verfasserin aut Influence of low molecular weight heparin on cancer patients’ survival 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p< ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival Diseases of the blood and blood-forming organs In Онкогематология ABV-press, 2015 8(2014), 2, Seite 70-76 (DE-627)1736704621 24134023 nnns volume:8 year:2014 number:2 pages:70-76 https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae kostenfrei http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 kostenfrei https://doaj.org/toc/1818-8346 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 2 70-76
allfieldsSound	(DE-627)DOAJ01920468X (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae DE-627 ger DE-627 rakwb rus RC633-647.5 V. V. Ptushkin verfasserin aut Influence of low molecular weight heparin on cancer patients’ survival 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p< ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival Diseases of the blood and blood-forming organs In Онкогематология ABV-press, 2015 8(2014), 2, Seite 70-76 (DE-627)1736704621 24134023 nnns volume:8 year:2014 number:2 pages:70-76 https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae kostenfrei http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 kostenfrei https://doaj.org/toc/1818-8346 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 2 70-76
language	Russian
source	In Онкогематология 8(2014), 2, Seite 70-76 volume:8 year:2014 number:2 pages:70-76
sourceStr	In Онкогематология 8(2014), 2, Seite 70-76 volume:8 year:2014 number:2 pages:70-76
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival Diseases of the blood and blood-forming organs
isfreeaccess_bool	true
container_title	Онкогематология
authorswithroles_txt_mv	V. V. Ptushkin @@aut@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	1736704621
id	DOAJ01920468X
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ01920468X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310204639.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ01920468X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC633-647.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. V. Ptushkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Influence of low molecular weight heparin on cancer patients’ survival</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ultra low molecular weight heparins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low molecular weight heparins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the blood and blood-forming organs</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Онкогематология</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">8(2014), 2, Seite 70-76</subfield><subfield code="w">(DE-627)1736704621</subfield><subfield code="x">24134023</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:70-76</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://oncohematology.abvpress.ru/index.php/ongm/article/view/36</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1818-8346</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2014</subfield><subfield code="e">2</subfield><subfield code="h">70-76</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	V. V. Ptushkin
spellingShingle	V. V. Ptushkin misc RC633-647.5 misc ultra low molecular weight heparins misc low molecular weight heparins misc cancer misc metastasis misc survival misc Diseases of the blood and blood-forming organs Influence of low molecular weight heparin on cancer patients’ survival
authorStr	V. V. Ptushkin
ppnlink_with_tag_str_mv	@@773@@(DE-627)1736704621
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	RC633-647
illustrated	Not Illustrated
issn	24134023
topic_title	RC633-647.5 Influence of low molecular weight heparin on cancer patients’ survival ultra low molecular weight heparins low molecular weight heparins cancer metastasis survival
topic	misc RC633-647.5 misc ultra low molecular weight heparins misc low molecular weight heparins misc cancer misc metastasis misc survival misc Diseases of the blood and blood-forming organs
topic_unstemmed	misc RC633-647.5 misc ultra low molecular weight heparins misc low molecular weight heparins misc cancer misc metastasis misc survival misc Diseases of the blood and blood-forming organs
topic_browse	misc RC633-647.5 misc ultra low molecular weight heparins misc low molecular weight heparins misc cancer misc metastasis misc survival misc Diseases of the blood and blood-forming organs
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Онкогематология
hierarchy_parent_id	1736704621
hierarchy_top_title	Онкогематология
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1736704621
title	Influence of low molecular weight heparin on cancer patients’ survival
ctrlnum	(DE-627)DOAJ01920468X (DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae
title_full	Influence of low molecular weight heparin on cancer patients’ survival
author_sort	V. V. Ptushkin
journal	Онкогематология
journalStr	Онкогематология
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	70
author_browse	V. V. Ptushkin
container_volume	8
class	RC633-647.5
format_se	Elektronische Aufsätze
author-letter	V. V. Ptushkin
title_sort	influence of low molecular weight heparin on cancer patients’ survival
callnumber	RC633-647.5
title_auth	Influence of low molecular weight heparin on cancer patients’ survival
abstract	<p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p<
abstractGer	<p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p<
abstract_unstemmed	<p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Influence of low molecular weight heparin on cancer patients’ survival
url	https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae http://oncohematology.abvpress.ru/index.php/ongm/article/view/36 https://doaj.org/toc/1818-8346
remote_bool	true
ppnlink	1736704621
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC633-647.5
up_date	2024-07-03T22:21:55.275Z
_version_	1803598236510846976
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ01920468X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310204639.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ01920468X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3de370bf73e54dbfbc08e90483da1cae</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC633-647.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. V. Ptushkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Influence of low molecular weight heparin on cancer patients’ survival</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. The<br /<promise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group of<br /<drugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point of<br /<view and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,<br /<semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).<br /<Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ultra low molecular weight heparins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low molecular weight heparins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the blood and blood-forming organs</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Онкогематология</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">8(2014), 2, Seite 70-76</subfield><subfield code="w">(DE-627)1736704621</subfield><subfield code="x">24134023</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:70-76</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3de370bf73e54dbfbc08e90483da1cae</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://oncohematology.abvpress.ru/index.php/ongm/article/view/36</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1818-8346</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2014</subfield><subfield code="e">2</subfield><subfield code="h">70-76</subfield></datafield></record></collection>
score	7.401145

Nicht das Richtige dabei?

Schreiben Sie uns!

Influence of low molecular weight heparin on cancer patients’ survival

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?